Kindeva's New Injectable Facility Marks Success With First Registration Batch

Kindeva Drug Delivery, a prominent global contract development and manufacturing organisation (CDMO), has reached two significant milestones at its advanced facility in Bridgeton, MO. The site has successfully produced its first registration batch using the groninger high-volume vial line. This accomplishment highlights the facility's preparedness to fulfil the increasing demand for injectable fill-finish services and represents an important advancement in the company’s growth strategy.

The first Optima line is set to arrive in November 2024, with plans to complete its qualification by the first quarter of 2025. Kindeva expects both Optima lines to be fully operational by the end of 2025, allowing for a production capacity of over 100 million units each year, including vials, cartridges, and syringes.

Industry experts and prospective partners are encouraged to visit Kindeva’s Booth #7D50 at the CPHI Worldwide conference in Milan, Italy. There, they can explore the new Bridgeton facility, which fully complies with Annex 1 standards, and engage in discussions about how Kindeva’s aseptic injectable fill-finish capabilities can meet their requirements.

Denis Johnson, Chief Operating Officer at Kindeva, said in a statement, “The completion of the first registration batch at the Bridgeton facility represents a significant milestone. This is the first of four lines planned to be installed in the next 18 months. Additionally, we are pleased to announce we have just successfully completed the Factory Acceptance Testing (FAT) on the first of two Optima syringe/cartridge filling lines planned for the new facility.”